Abeta(25-35) as proxyholder for amyloidogenic peptides: in vivo evidence.
Gulyaeva
Natalia V
NV
Institute of Higher Nervous Activity & Neurophysiology, Russian Academy of Sciences, 5a Butlerov Street, Moscow 117485, Russia. nata_gul@pisem.net
Stepanichev
Mikhail Y
MY
D000544:Alzheimer Disease / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D009422:Nervous System Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D010446:Peptide Fragments / Q000378:metabolism* / Q000494:pharmacology / Q000633:toxicity
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); C074636:amyloid beta-protein (25-35); D009569:Nitric Oxide